| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1002/CNCR.21886 |
| P698 | PubMed publication ID | 16649217 |
| P50 | author | Diana Giannarelli | Q44736865 |
| Emilio Bria | Q46978152 | ||
| P2093 | author name string | Paolo Carlini | |
| Michele Milella | |||
| Francesco Cognetti | |||
| Mariangela Ciccarese | |||
| Guido Natoli | |||
| Cecilia Nistico | |||
| Edmondo Terzoli | |||
| Federica Cuppone | |||
| P2860 | cites work | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| Cancer statistics, 2002 | Q28216788 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results | Q34524041 | ||
| Meta-analyses of randomised clinical trials in oncology. | Q34571922 | ||
| Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer | Q38446760 | ||
| Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. | Q44362100 | ||
| Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. | Q46493659 | ||
| Adjuvant docetaxel for node-positive breast cancer | Q46522790 | ||
| Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group | Q46691182 | ||
| Meta-analyses based on abstracted data: a step in the right direction, but only a first step. | Q52966519 | ||
| Interpreting Measures of Treatment Effect in Cancer Clinical Trials | Q56020813 | ||
| Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma | Q61900024 | ||
| Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer | Q73384968 | ||
| Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute | Q74082953 | ||
| Effect of preoperative chemotherapy on the outcome of women with operable breast cancer | Q77093352 | ||
| Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women | Q77435888 | ||
| Trastuzumab in the treatment of breast cancer | Q81374982 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2337-2344 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients | |
| P478 | volume | 106 |
| Q35994850 | A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study |
| Q37081127 | A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer |
| Q37099589 | Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens |
| Q37037373 | Advances in the treatment of breast cancer |
| Q47138534 | Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer |
| Q55347754 | Beta-hydroxybutyrate (3-OHB) can influence the energetic phenotype of breast cancer cells, but does not impact their proliferation and the response to chemotherapy or radiation. |
| Q37797755 | Bisphosphonates as Anticancer Therapy for Early Breast Cancer |
| Q37730641 | Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years? |
| Q36976929 | Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer |
| Q51732668 | Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand |
| Q36671882 | Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer |
| Q37015628 | Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials |
| Q33800180 | Docetaxel does not impair skeletal muscle force production in a murine model of cancer chemotherapy |
| Q44168101 | Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials |
| Q87314756 | Effectiveness and complications of anthracycline and taxane in the therapy of breast cancer: a meta-analysis |
| Q37903140 | Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials |
| Q36278585 | Evaluating the efficacy of current clinical practice of adjuvant chemotherapy in postmenopausal women with early-stage, estrogen or progesterone receptor-positive, one-to-three positive axillary lymph node, breast cancer |
| Q34726680 | Expression and Silencing of the Microtubule-Associated Protein Tau in Breast Cancer Cells |
| Q36102798 | Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial |
| Q34537146 | Factors responsible for long-term survival in metastatic breast cancer |
| Q34274152 | GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy |
| Q61899519 | Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress? |
| Q37583394 | Genetic inactivation and pharmacological blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve mitochondrial abnormalities and neuropathic pain in mice |
| Q45218109 | Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ? |
| Q36953443 | Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypes |
| Q37657782 | Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012. |
| Q60050114 | Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Adva |
| Q33933669 | Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials |
| Q37641082 | Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more |
| Q37065942 | Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer |
| Q34000716 | Organizing medical oncology care at a regional level and its subsequent impact on the quality of early breast cancer management: a before-after study |
| Q36718459 | PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer |
| Q35889568 | Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial |
| Q37119462 | Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. |
| Q36740694 | RCT of a psychological intervention for patients with cancer: I. mechanisms of change |
| Q64237541 | Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer |
| Q37208730 | Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. |
| Q36092813 | Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer |
| Q36672852 | Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years |
| Q44869105 | Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials |
| Q24242987 | Taxanes for adjuvant treatment of early breast cancer |
| Q36681504 | Taxanes in breast cancer: an update |
| Q37649479 | Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer |
| Q36449309 | Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer |
| Q46008999 | Unravelling the mystery of the TACT trial. |
| Q79298416 | [Treatment of breast cancer: from hormones to antibodies] |
Search more.